Építés alatt – nem éles oldal
Belépés
Csak meghívásos1. fázis

Phase Ib Trial of Injectable RAB001 for Knee Osteoarthritis

A legfontosabb adatok

Ki végzi
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Hol
Kína2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Csak meghívásos
Fázis
1. fázis
Résztvevők
60 fő, tervezett
Kezdés
2026. ápr. 16.
Várható befejezés
2027. szept. 30.
A vizsgálat típusa
Beavatkozással járó, 5 csoport
A vizsgált kezelések
  • RAB001 medium dose
A regiszteradat frissítve
2026. június 17.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with knee osteoarthritis who still have knee pain despite other care. They get RAB001 or placebo injected into the knee.

Életkor
40 to 75 years
Nem
All sexes
A betegség stádiuma
Knee osteoarthritis, Kellgren-Lawrence Grade I-III in the target knee. The other knee must not have a higher grade. Walking pain score (VAS of WOMAC Item A1) of ≥40 mm and ≤80 mm. BMI 18 to 30 kg/m².
Korábbi kezelés
At least 4 weeks of conservative care (for example physical therapy, painkillers) with ongoing knee pain. No steroid or hyaluronate injection into the target knee in the 24 weeks before screening. No systemic corticosteroids in the 12 weeks before screening.

A részvétel fő kizáró okai

  • Osteoarthritis of the hip on the same side, or pain of 40 mm or more in another joint
  • Inflammatory joint disease such as rheumatoid arthritis, gout or psoriatic arthritis
  • Knee or other major leg surgery in the 24 weeks before screening, or leg surgery planned during the trial
  • Active cancer or cancer treatment in the past 5 years, except non-melanoma skin cancer
  • Pregnancy, breastfeeding, or not willing to use effective birth control

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • (1) Aged from 40 to 75 years inclusive; (2) Diagnosis of knee osteoarthritis consistent with the diagnostic criteria in the Guidelines for the Diagnosis and Treatment of Osteoarthritis issued by the Joint Surgery Group, Orthopaedic Branch of Chinese Medical Association (2024); (3) Received conservative management (e.g., physical therapy, analgesics) for ≥4 weeks with persistent pain in the target knee; the VAS score of WOMAC Item A1 (walking pain) is ≥40 mm and ≤80 mm at screening and baseline; (4) Target knee is graded as Kellgren-Lawrence Grade I-III; the contralateral knee shall not have a higher KL grade than the target knee. In case of identical grades for both knees, the right knee is defined as the target knee; (5) Body mass index (BMI) ranges from 18 to 30 kg/m² inclusive; (6) Provides written informed consent voluntarily prior to any study-related procedures

Ki nem vehet részt

  • (1) Unable to ambulate (subjects using walking aids for ≥12 weeks prior to screening visit may continue such aids throughout the study); (2) VAS pain score ≥40 mm in any joint other than the target knee at screening and baseline visits; (3) Subjects with osteoarthritis of the ipsilateral hip; (4) Subjects with substantial target-knee joint effusion judged by the investigator to be ineligible for enrollment; (5) Subjects with active septic arthritis of the target knee, skin breakdown/infection at the injection site, or any significant chronic dermatosis that may interfere with intra-articular injection and/or injection-site safety assessment; (6) Subjects unable to discontinue permitted analgesics within 48 hours prior to efficacy assessments; (7) Subjects receiving systemic corticosteroids within 12 weeks before screening; (8) Subjects with septic arthritis in any joint within 12 weeks before screening; (9) Subjects exposed to any investigational medicinal product, device or biologic within 12 weeks before screening; (10) Subjects receiving intra-articular corticosteroid injection into the target knee within 24 weeks before screening; (11) Subjects receiving viscosupplementation injection (sodium hyaluronate, medical chitosan) in the target knee within 24 weeks before screening; (12) Subjects who underwent major lower-extremity surgery, arthroplasty or arthroscopy on target knee or other lower-limb joints within 24 weeks before screening, or with planned lower-limb surgery during study period; (13) Subjects with secondary knee osteoarthritis induced by acute disease or trauma within 5 years before screening; (14) Subjects with active malignancy or history of anti-tumor therapy within 5 years before screening, excluding non-melanoma skin cancer; (15) Subjects with inflammatory arthropathies or relevant disorders involving joints (e.g., rheumatoid arthritis, metabolic bone disease, psoriatic arthritis, gout, symptomatic chondrocalcinosis, osteonecrosis or active infection); (16) Subjects with marked varus/valgus deformity, ligamentous laxity or unstable meniscus; (17) Subjects with chronic painful conditions (VAS ≥40 mm) at screening or peripheral/central neuropathy impairing sensory function around target knee, including but not limited to back pain, hip pain, intervertebral disc herniation, sciatica, diabetic neuropathy, post-stroke pain or fibromyalgia; (18) Subjects with pulmonary diseases such as asthma or COPD requiring regular systemic/inhaled corticosteroid treatment during study; (19) Subjects with venous or lymphatic stasis of lower extremities; (20) Subjects with claudication or peripheral arterial disease; (21) Subjects on ongoing oral/parenteral anticoagulation or high-dose antiplatelet therapy (daily aspirin ≤100 mg and/or antiplatelet agents such as clopidogrel, ticagrelor are permitted); (22) Subjects on chronic regular intake of paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs); (23) Subjects with severe systemic illnesses including myocardial infarction, heart failure, unstable angina, cerebrovascular disease, severe renal insufficiency, etc.; (24) Subjects with severe hepatic impairment or relevant medical history; (25) Subjects with abnormal coagulation parameters; (26) Subjects with known hypersensitivity to any component of investigational product or paracetamol, or severe allergic constitution as assessed by investigator; (27) Female subjects with positive pregnancy test, breastfeeding, unwilling to implement effective contraception or planning pregnancy during trial; (28) Subjects with any other conditions deemed inappropriate for study enrollment by the investigator

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 40 és 75 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a randomized, double-blind, placebo-controlled dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of intra-articular injection of RAB001 in participants with knee osteoarthritis (KOA).

A teljes eredeti leírásKevesebb

The study consists of five dose groups: 1.5 mg, 4.5 mg, 9 mg, 18 mg and 27 mg. A total of 12 participants with knee osteoarthritis will be enrolled per dose group (9 receiving investigational product and 3 receiving placebo), for an overall total enrollment of 60 subjects. The 27 mg cohort serves as an optional escalation group, whose initiation is contingent upon assessment by the Safety Review Committee (SRC).

Eligible participants will first receive a single-dose administration followed by a 14-day observation period, during which safety, tolerability, PK and preliminary efficacy data will be collected.

In the multiple-dose phase, study treatment will be administered once every 4 weeks for a total of 2 injections, on Week 4 (Day 29) and Week 8 (Day 57), respectively. After the last administration, subjects will enter the follow-up period and return to the study site for safety and efficacy assessments at Weeks 12, 16 and 24.

A staggered dose-escalation design will be implemented. Escalation to the next higher dose level may proceed only after completion of the 14-day safety and tolerability evaluation for all subjects in the current dose cohort and subsequent approval from the SRC. Each participant will receive only one assigned dose level throughout the trial.

A vizsgálat 5 csoportja

  • 1.5 mgA vizsgált kezelés

    9 subjects and 3 receive placebo.

    Kezelés: RAB001 medium dose

  • 4.5 mgA vizsgált kezelés

    9 subjects and 3 receive placebo.

    Kezelés: RAB001 medium dose

  • 9 mgA vizsgált kezelés

    9 subjects and 3 receive placebo.

    Kezelés: RAB001 medium dose

  • 18 mgA vizsgált kezelés

    9 subjects and 3 receive placebo.

    Kezelés: RAB001 medium dose

  • 27 mgA vizsgált kezelés

    9 subjects and 3 receive placebo.The 27 mg cohort is an optional dose-escalation group, and its implementation will be determined based on the assessment from the Safety Review Committee (SRC).

    Kezelés: RAB001 medium dose

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Intra-Articular Injection of RAB001 for Injection in Participants With Knee Osteoarthritis
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07652372: ki vehet részt
A regiszteradat frissítve
2026. június 17.